Načítá se...

A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record

OBJECTIVE: Recently, the European Medicines Agency reported that strontium ranelate increases myocardial infarction risk in postmenopausal women, 8.5 years after it was registered for use in osteoporosis. Unreported serious adverse events in clinical trials for other pharmaceuticals have been descri...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bolland, Mark J, Grey, Andrew
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2014
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4187454/
https://ncbi.nlm.nih.gov/pubmed/25293384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-005787
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!